Real-World Evidence For Accelerated Approval: NASEM Is A Tough Crowd
• By Michael McCaughan
A NASEM panelist said real world data likely would be biased if used to confirm small or moderate effects after an accelerated approval. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
